Skip to Content

Coraxis

This page contains information on Coraxis for veterinary use.
The information provided typically includes the following:
  • Coraxis Indications
  • Warnings and cautions for Coraxis
  • Direction and dosage information for Coraxis

Coraxis

This treatment applies to the following species:

(moxidectin) Topical Solution for Dogs

Company: Bayer Animal Health

Once-a-month topical solution for the prevention of heartworm disease caused by Dirofilaria immitis, as well as the treatment and control of intestinal hookworm, roundworm and whipworm infections in dogs and puppies that are at least 7 weeks of age and that weigh at least 3 lbs.

WARNING

DO NOT ADMINISTER THIS PRODUCT ORALLY

For the first 30 minutes after application ensure that dogs cannot lick the product from application sites on themselves or other treated animals.

Children should not come in contact with application sites for two (2) hours after application.

(See Contraindications, Warnings, Human Warnings, and Adverse Reactions, for more information.)

Coraxis Caution

Federal (U.S.A.) Law restricts this drug to use by or on the order of a licensed veterinarian.

Description

CORAXIS™ (2.5% moxidectin) is a colorless to yellow, ready-to-use solution packaged in single dose applicator tubes for topical treatment of dogs. The formulation and dosage schedule are designed to provide a minimum of 1.1 mg/lb (2.5 mg/kg) moxidectin based on body weight.

Moxidectin is a semisynthetic macrocyclic lactone endectocide derived from the actinomycete Streptomycetes cyaneogriseus noncyanogenus. The chemical name for moxidectin is [6R,23E,25S(E)]-5-O-Demethyl-28-deoxy-25-(1,3-dimethyl-1-butenyl)-6,28-epoxy-23-(methoxyimino) milbemycin B.

Coraxis Indications

CORAXIS is indicated for the prevention of heartworm disease caused by Dirofilaria immitis. CORAXIS is also indicated for the treatment and control of the following intestinal parasites:

Intestinal Parasite

Intestinal Stage

Adult

Immature Adult

Fourth Stage Larvae

Hookworm Species

Ancylostoma caninum

X

X

X

Uncinaria stenocephala

X

X

X

Roundworm Species

 

Toxocara canis

X

 

X

Toxascaris leonina

X

 

 

Whipworm

Trichuris vulpis

X

 

 

Contraindications

Do not administer this product orally. (See WARNINGS.)

Do not use this product (containing 2.5% moxidectin) on cats.

Warnings

For the first 30 minutes after application:

Ensure that dogs cannot lick the product from application sites on themselves or other treated dogs, and separate treated dogs from one another and from other pets to reduce the risk of accidental ingestion.

Ingestion of this product by dogs may cause serious adverse reactions including depression, salivation, dilated pupils, incoordination, panting, and generalized muscle tremors.

In avermectin sensitive dogs,a the signs may be more severe and may include coma and death.b

a Some dogs are more sensitive to avermectins due to a mutation in the ABCB1 gene (formerly MDR1 gene). Dogs with this mutation may develop signs of severe avermectin toxicity if they ingest this product. The most common breeds associated with this mutation include Collies and Collie crosses.

b Although there is no specific antagonist for avermectin toxicity, even severely affected dogs have completely recovered from avermectin toxicity with intensive veterinary supportive care.

HUMAN WARNINGS:

Not for human use. Keep out of the reach of children.

Children should not come in contact with application sites for two (2) hours after application. Causes eye irritation. Harmful if swallowed. Do not get in eyes or on clothing. Avoid contact with skin. Exposure to the product has been reported to cause headache; dizziness; and redness, burning, tingling, or numbness of the skin. Wash hands thoroughly with soap and warm water after handling.

If contact with eyes occurs, hold eyelids open and flush with copious amounts of water for 15 minutes. If eye irritation develops or persists, contact a physician. If swallowed, call poison control center or physician immediately for treatment advice. Have person sip a glass of water if able to swallow. Do not induce vomiting unless told to do so by the poison control center or physician. People with known hypersensitivity to benzyl alcohol or moxidectin should administer the product with caution. In case of allergic reaction, contact a physician. If contact with skin or clothing occurs, take off contaminated clothing. Wash skin immediately with plenty of soap and water. Call a poison control center or physician for treatment advice.

The Safety Data Sheet (SDS) provides additional occupational safety information. For a copy of the Safety Data Sheet (SDS) or to report adverse reactions call Bayer Veterinary Services at 1-800-422-9874. For consumer questions call 1-800-255-6826.

Precautions

Do not dispense dose applicator tubes without complete safety and administration information.

Use with caution in sick, debilitated, or underweight animals. The safety of CORAXIS has not been established in breeding, pregnant, or lactating dogs. The safe use of CORAXIS has not been established in puppies and dogs less than 7 weeks of age or less than 3 lbs body weight.

Prior to administration of CORAXIS, dogs should be tested for existing heartworm infection. At the discretion of the veterinarian, infected dogs should be treated with an adulticide to remove adult heartworms.

CORAXIS is not effective against adult D. immitis. (See ANIMAL SAFETY - Safety Study in Heartworm-Positive Dogs.)

Adverse Reactions

Since CORAXIS contains 2.5% moxidectin, studies that demonstrated the safe use of a topical solution containing 2.5% moxidectin + 10% imidacloprid were acceptable to demonstrate the safety of CORAXIS.

Field Studies: Following treatment with a topical solution containing 2.5% moxidectin + 10% imidacloprid or an active control, dog owners reported the following post-treatment reactions:

OBSERVATION

Moxidectin + Imidacloprid

n = 128

Active Control

n = 68

Pruritus

19 dogs (14.8%)

7 dogs (10.3%)

Residue

9 dogs (7.0%)

5 dogs (7.4%)

Medicinal Odor

5 dogs (3.9%)

None observed

Lethargy

1 dog (0.8%)

1 dog (1.5%)

Inappetence

1 dog (0.8%)

1 dog (1.5%)

Hyperactivity

1 dog (0.8%)

None observed

During a field study of a topical solution containing 2.5% moxidectin + 10% imidacloprid using 61 dogs with pre-existing flea allergy dermatitis, one (1.6%) dog experienced localized pruritus immediately after product application, and one investigator noted hyperkeratosis at the application site of one dog (1.6%).

Laboratory Effectiveness Studies: One dog in a laboratory effectiveness study experienced weakness, depression and unsteadiness between 6 and 9 days after application of a topical solution containing 2.5% moxidectin + 10% imidacloprid. The signs resolved without intervention by day 10 post-application. The signs in this dog may have been related to peak serum levels of moxidectin, which vary between dogs, and occur between 1 and 21 days after product application.

The following clinical observations also occurred in laboratory effectiveness studies following application of a topical solution containing 2.5% moxidectin + 10% imidacloprid and may be directly attributed to the drug or may be secondary to the intestinal parasite burden or other underlying conditions in the dogs: diarrhea, bloody stools, vomiting, anorexia, lethargy, coughing, ocular discharge and nasal discharge. Observations at the application sites included damp, stiff or greasy hair, the appearance of a white deposit on the hair, and mild erythema, which resolved without treatment within 2 to 48 hours.

Foreign Market Experience: Because the following events were reported voluntarily during post-approval use of the product containing 2.5% moxidectin + 10% imidacloprid in foreign markets, it is not always possible to reliably establish a causal relationship to drug exposure. Adverse events associated with CORAXIS (2.5% moxidectin) are expected to be similar.

The following adverse events were reported in humans: eye irritation, allergic reactions, skin irritation, skin tingling, sore throat and chemical odor. Adverse events reported in dogs topically treated with a topical solution containing 2.5% moxidectin + 10% imidacloprid included: vomiting, diarrhea, bloody diarrhea, salivation, poor appetite, lethargy, weakness, restlessness, agitation, disorientation, ataxia, muscle tremors, seizures, panting, labored breathing, acute pulmonary edema, hives, rash, swollen face and ears, pruritus, erythema, alopecia, hot spots, local discomfort and discoloration of the hair at the application site. Accidental oral ingestion in dogs caused salivation, vomiting, muscle tremor, seizures, mydriasis, ataxia, lethargy, disorientation, agitation and poor appetite.

Adverse events in cats topically treated with imidacloprid + moxidectin for dogs included application site and skin reactions, vomiting, lethargy, agitation and neurologic signs.

To report a suspected adverse reaction, call 1-800-422-9874.

Dosage and Administration

The recommended minimum dose is 1.1 mg/lb (2.5 mg/kg) moxidectin, once-a-month, by topical administration.

Do not apply to irritated skin.

1. Remove one dose applicator tube from the package. As specified in the following table, administer the entire contents of the CORAXIS tube that correctly corresponds with the body weight of the dog.

Dog Weight

(lbs)

CORAXIS

Volume

(mL)

Moxidectin

(mg)

3-9

CORAXIS 9

0.4

10

9.1-20

CORAXIS 20

1.0

25

20.1-55

CORAXIS 55

2.5

62.5

55.1-88

CORAXIS 88

4.0

100

88.1-110*

CORAXIS 110

5.0

125

*Dogs over 110 lbs. should be treated with the appropriate combination of CORAXIS tubes.

2. While holding the tube in an upright position, remove the cap from the tube.

3. Turn the cap over and push the other end of cap onto the tip of the tube.

4. Twist the cap to break the seal and then remove cap from the tube.

5. The dog should be standing for application. Part the hair on the back of the dog between the shoulder blades until the skin is visible. For dogs weighing 20 lbs or less, place the tip of the tube on the skin and apply the entire contents directly on the exposed skin at one spot between the shoulder blades. For dogs weighing more than 20 lbs, place the tip of the tube on the skin and apply the entire contents directly on the exposed skin at 3 or 4 spots on the top of the backline from the base of the neck to the upper back in an area inaccessible to licking. Do not apply an amount of solution at any one location that could run off the side of the dog.

Do not let this product get in your dog’s mouth or eyes. Do not allow the dog to lick any of the application sites for 30 minutes. In households with multiple pets, keep each treated dog separated from other treated dogs and other pets for 30 minutes after application to prevent licking the application sites. (See WARNINGS.)

Stiff hair, a damp appearance of the hair, pink skin or a slight powdery residue may be observed at the application site on some animals. This is temporary and does not affect the safety and effectiveness of the product.

Shampooing 90 minutes after treatment does not reduce the effectiveness of CORAXIS in the prevention of heartworm disease.

Heartworm Prevention: For prevention of heartworm disease, CORAXIS should be administered at one-month intervals. CORAXIS may be administered year-round or at a minimum should start one month before the first expected exposure to mosquitoes and should continue at monthly intervals until one month after the last exposure to mosquitoes. If a dose is missed and a 30-day interval between doses is exceeded, administer CORAXIS immediately and resume the monthly dosing schedule. When replacing another heartworm preventative product in a heartworm prevention program, the first treatment with CORAXIS should be given within one month of the last dose of the former medication.

Treatment and Control of Intestinal Nematode Infections:

For the treatment and control of intestinal hookworm infections caused by Ancylostoma caninum and Uncinaria stenocephala (adults, immature adults and fourth-stage larvae) and roundworm infections caused by Toxocara canis (adults and fourth-stage larvae), and Toxascaris leonina (adults), and whipworm infections caused by Trichuris vulpis (adults), CORAXIS should be administered once as a single topical dose.

ANIMAL SAFETY:

In a controlled, double-masked, field safety study, a topical solution containing 2.5% moxidectin + 10% imidacloprid was administered to 128 dogs of various breeds, 3 months to 15 years of age, weighing 4 to 157 pounds. The moxidectin + imidacloprid topical solution was used safely in dogs concomitantly receiving ACE inhibitors, anticonvulsants, antihistamines, antimicrobials, chondroprotectants, corticosteroids, immunotherapeutics, MAO inhibitors, NSAIDs, ophthalmic medications, sympathomimetics, synthetic estrogens, thyroid hormones, and urinary acidifiers. Owners reported the following signs in their dogs after application of moxidectin + imidacloprid topical solution: pruritus, flaky/greasy residue at the treatment site, medicinal odor, lethargy, inappetence and hyperactivity. (See ADVERSE REACTIONS.)

Safety Study in Puppies: A solution containing 2.5% moxidectin + 10% imidacloprid was applied topically at 1, 3 and 5x the recommended dose to 7-week-old Beagle puppies once every 2 weeks for 6 treatments on days 0, 14, 28, 42, 56, and 70. Loose stools and diarrhea were observed in all groups, including the controls, throughout the study. Vomiting was seen in one puppy from the 1x treatment group (day 57), in two puppies from the 3x treatment group (days 1 and 79), and in one puppy from the 5x treatment group (day 1). Two puppies each in the 1x, 3x and 5x groups had decreased appetites within 24 hours post-dosing. One puppy in the 1x treatment group had pruritus for one hour following the fifth treatment. A puppy from the 5x treatment group displayed rapid, difficult breathing from 4 to 8 hours following the second treatment.

Dermal Dose Tolerance Study: A solution containing 2.5% moxidectin + 10% imidacloprid was administered topically to 8-month-old Beagle dogs once at 10x the recommended dose. One dog showed signs of treatment site irritation after application. Two dogs vomited, one at 6 hours and one at 6 days post-treatment. Increased RBC, hemoglobin, activated partial thromboplastin and direct bilirubin were observed in the treated group. Dogs in the treated group did not gain as much weight as the control group.

Safety Study in Heartworm-Positive Dogs: A solution containing 2.5% moxidectin + 10% imidacloprid was administered topically at 1 and 5x the recommended dose every 14 days for 3 treatments to dogs with adult heartworm infections and circulating microfilariae. At 5x, one dog was observed vomiting three hours after the second treatment. Hypersensitivity reactions were not seen in the 5x treatment group. Microfilariae counts decreased with treatment.

Oral Safety Study in Beagles: A solution containing 2.5% moxidectin + 10% imidacloprid was administered once orally at the recommended topical dose to 12 dogs. Six dogs vomited within 1 hour of receiving the test article, 2 of these dogs vomited again at 2 hours, and 1 dog vomited again at 18 hours post-dosing. One dog exhibited shaking (nervousness) 1 hour post-dosing. Another dog exhibited abnormal neurological signs (circling, ataxia, generalized muscle tremors and dilated pupils with a slow pupillary light response) starting at 4 hours post-dosing through 18 hours post-dosing. Without treatment, this dog was neurologically normal at 24 hours and had a normal appetite by 48 hours post-dosing. (See CONTRAINDICATIONS.)

Dermal Safety Study in Ivermectin-Sensitive Collies: A solution containing 2.5% moxidectin + 10% imidacloprid was administered topically at 3 and 5x the recommended dose every 28 days for 3 treatments to Collies which had been pre-screened to confirm avermectin sensitivity. No clinical abnormalities were observed.

Oral Safety Study in Ivermectin-Sensitive Collies: A solution containing 2.5% moxidectin + 10% imidacloprid was administered orally to 5 pre-screened ivermectin-sensitive Collies. The Collies were asymptomatic after ingesting 10% of the minimum labeled dose. At 40% of the minimum recommended topical dose, 4 of the dogs experienced neurological signs indicative of avermectin toxicity including depression, ataxia, mydriasis, salivation, muscle fasciculation and coma, and were euthanized. (See CONTRAINDICATIONS.)

STORAGE INFORMATION:

Store at temperatures between 4°C (39°F) and 25°C (77°F), avoiding excess heat or cold.

How Supplied

Applications Per Package

6 x 0.4 mL tubes

6 x 1.0 mL tubes

6 x 2.5 mL tubes

6 x 4.0 mL tubes

6 x 5.0 mL tubes

NADA #141-417, Approved by FDA

Bayer HealthCare LLC, Animal Health Division, P.O. Box 390, Shawnee Mission, Kansas 66201 U.S.A.

LV1808

©2018 Bayer HealthCare LLC

Bayer (reg’d), the Bayer Cross (reg’d) and Coraxis™ are trademarks of Bayer.

Regulations for product use are established by country. Information contained on this site pertains only to the United States of America, and is not intended to provide adequate information for product use. Before using or dispensing any product, read and carefully observe the label directions.

BAYER HEALTHCARE LLC
Animal Health Division

P.O. BOX 390, SHAWNEE MISSION, KS, 66201-0390
Customer Service Tel.:   800-633-3796
Customer Service Fax:   800-344-4219
Website:   www.bayer-ah.com
   
Every effort has been made to ensure the accuracy of the Coraxis information published above. However, it remains the responsibility of the readers to familiarize themselves with the product information contained on the US product label or package insert.

Copyright © 2019 Animalytix LLC. Updated: 2019-09-30

Hide